Screener
ImmunityBio, Inc. IBRX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s EBITDA?
- ImmunityBio, Inc. (IBRX) reported EBITDA of -$65.41M in Q1 2026.
- How has ImmunityBio, Inc.'s EBITDA changed year-over-year?
- ImmunityBio, Inc.'s EBITDA decreased by 7.9% year-over-year, from -$60.6M to -$65.41M.
- What is the long-term trend for ImmunityBio, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s EBITDA has grown at a -6.6% compound annual growth rate (CAGR), from -$316.04M to -$240.5M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about ImmunityBio, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude